BioSpace News Archive

Kriya Therapeutics, Inc. announced today that it has appointed Curt Herberts, M.B.S., as President and Chief Operating Officer. Herberts will oversee all general and administrative functions at Kriya.

AltrixBio , an emerging early-stage biotech startup, is presenting an abstract on LuCI™, a repurposed pill that adheres to the gastrointestinal (GI) tract for controlled GI targeting.

IIOT-OXYS, Inc. (OTC PINK:ITOX) announced its financial results for its second quarter ended June 30, 2022, and an upcoming Investor Conference Call on Tuesday, August 30, 2022.

Orthopedic Surgeon Cesar E. Ceballos, MD, FAAOS, Founder of OrthoMiami in Miami, Florida, announced a successful surgical intervention in a 19-year-old male using the FDA-cleared BEAR® Implant, manufactured by Miach Orthopedics, to repair an anterior cruciate ligament tear without necessity of a live or donor tendon graft.

Based on promising research conducted at Terasaki Institute for Biomedical Innovation (TIBI) the Company is pleased to announce that it has selected its final lead drug candidate from a short list of six DMT analogue molecules and intends to submit a provisional patent in Q4, 2022 detailing the novel uses and dosage forms of its lead candidate, and medical device for the treatment of primary open angle glaucoma (POAG).

Can-Fite BioPharma Ltd today announced financial results for the quarter ended June 30, 2022.

Hangzhou Tigermed Consulting Co., Ltd. announced its interim results for the first half of 2022, ended June 30, 2022.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced results from the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s investigational anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS), were published in The New England Journal of Medicine (NEJM).

Stoke Therapeutics today announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA).

BiondVax Pharmaceuticals Ltd. today published its financial results for the quarter ended June 30, 2022 and provided a business update.